EuBiologics, the world's No. 1 cholera vaccine manufacturer,  said it will seek global partners by promoting its proprietary vaccine manufacturing technology, products and platform at the 2023 BIO International Convention (BIO 2023), to be held in Boston, the U.S., from June 5 to 8.

EuBiologics is the only company in the world to provide cholera vaccines to the public market.

Last year, the company delivered more than 30 million doses of cholera vaccine worldwide.

EuBiologics is developing a variety of new products utilizing its specialized technology and experience in vaccine development. 

Since the successful launch of the cholera vaccine Euvichol in late 2015, the company has been working on follow-up products such as vaccines for intestinal infections and cancer prevention.

Euvichol development experience leads to premium virus vaccines 

EuBiologics' flagship product, Euvichol-Plus, is an orally administered cholera vaccine that has the advantage of not causing localized adverse events such as pain in the vaccination site, edema, and rash. It is also supplied to underdeveloped countries through the WHO, the United Nations Children's Fund (UNICEF), and the Global Alliance for Vaccines and Immunization (GAVI) because it does not require a separate buffer and is affordable. In addition, it is manufactured in a single-use plastic tube formulation that is easier to store, transport and administer orally. The vaccine received WHO PQ in August 2017.

EuBiologics is working on bacterial vaccines (typhoid, pneumococcal and meningococcal vaccines) based on its proprietary EuBiologics Vaccine Conjugation Technology (EuVCT). 

The company is also developing a Covid-19 vaccine, EuCorvac-19, based on its EuBiologics Immune Modulation Technology (EuIMT). It is almost near the completion of a phase 3 trial of its Covid-19 vaccine.

EuBiologics said it will further develop premium virus vaccines to fight the respiratory syncytial virus (RSV) and shingles in the global market. The company plans to file a phase 1 trial plan for an RSV vaccine in the third quarter of this year, and a phase 1 study for a shingles vaccine in the fourth quarter.

EuIMT is an immunization technology that combines EcML (TLR4 Agonist) with a recombinant antigen to induce antibody production and cellular immunity. EuVCT maximizes the antibody production performance of weak antigenic polysaccharides by conjugating carrier proteins to polysaccharide antigens. EuBiologics is developing vaccines utilizing these platform technologies.

EuBiologics to meet with over 20 global companies at US event

EuBiologics plans to introduce its platform technologies at BIO 2023 and seek opportunities for technology transfer.

Specifically, the company will pitch licensing out EuIMT and EuVCT or supplying CRM197 and EcML as raw materials to other companies. It will also promote and seek a chance to co-develop RSV and shingles vaccines. It will also look for companies to collaborate on clinical trials of vaccines in the clinical stage (typhoid vaccine, meningococcal vaccine, and pneumococcal vaccine).

At BIO 2023, EuBiologics plans to hold discussions with more than 20 companies on licensing out, co-development, CMO, and new platforms.

"Joint discussions are scheduled with several companies in the U.S., including our affiliated company POP Biotech and multinational pharmaceuticals, on the development of anti-cancer vaccines (therapeutics)," an official at EuBiologics said. 

For EuCorVac-19, RSV, and HZV, which are currently under development, EuBiologics is combining the SNAP technology (antigen display) of POP Biotech and Eubiologics' EuIMT technology, the official went on to say.

“We will find a new platform that can be combined with our platform technology to develop next-generation anti-cancer vaccines and therapeutics."